Skip to search formSkip to main contentSkip to account menu

naptumomab estafenatox

A recombinant fusion protein consisting of the antigen-binding fragment of a monoclonal antibody directed towards the tumor-associated oncofetal… 
National Institutes of Health

Related topics

Related topics

6 relations

Narrower (1)

ABR-217620

Broader (3)

EnterotoxinsImmunoconjugatesMonoclonal Antibodies
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract 2712: Naptumomab Estafenatox induces T cell recognition, turning anti-PD-1 unresponsive "cold" tumors into "hot" responsive tumors
Tumor recognition is a key factor in checkpoint inhibitors (CPI) efficacy and acquired resistance. Lack or loss of tumor antigens… 
2016
2016
Kidney cancer: Naptumomab estafenatox ineffective in RCC
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)